TOKYO, Mar 25 (Pulse News Wire) – RaQualia Pharma Inc. (4579.T) resolved today to issue restricted shares as part of its equity compensation plan for directors.
The issuance, scheduled for April 24, 2026, involves issuing ordinary shares worth ¥795 per share, totaling ¥10.2 million. Two directors will receive the shares subject to restrictions until their tenure ends. The program was approved in February 2022 to incentivize long-term value creation and align interests with shareholders. Each director will receive up to ¥15 million annually in cash compensation, which will be converted into restricted stock grants within the existing remuneration framework.
The total number of shares granted annually cannot exceed 15,000. Under the agreement, directors cannot sell or pledge the shares during the restriction period, which runs from the payment date to the end of their tenure. Restrictions will lift upon completion of the vesting period or earlier if certain conditions are met, such as death or resignation due to valid reasons. In case of breach, the company retains the right to reclaim the shares without compensation.
The issuance price is set based on the closing price of RaQualia's ordinary shares on the Tokyo Stock Exchange on March 24, 2026, ensuring fairness and reflecting the company’s valuation accurately.
🟡 Confidence: Standard AI-translated content.